Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of results from three clinical trials of VELCADE based therapies that showed consistently high complete remission(1) (CR) rates in patients with newly diagnosed multiple myeloma (MM). CR is one of the best predictors of long-term survival. These three studies were selected for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 30 - June 3, 2008. Highlights included:

-- VELCADE, cyclophosphamide, and dexamethasone (CyBorD) demonstrated a

CR rate of 46 percent prior to transplant and 72 percent

post-transplant

-- VELCADE, DOXIL and dexamethasone (PAD or VcDD) prior to transplant

showed a CR rate of 21 percent which increased to 59 percent

post-transplant

-- VELCADE, lenalidomide and dexamethasone (VRD) showed a CR rate of 35

percent at maximum planned dose and a 100 percent overall response

rate.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The goal of first-line therapy is to rapidly achieve the deepest and most durable response possible," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "VELCADE based combinations produce among the highest CR rates that are similar to those achieved by high dose therapy and transplantation. These very strong results underscore the critical role of VELCADE in patients with newly diagnosed multiple myeloma."

Efficacy of Induction with CyBorD in Newly Diagnosed Multiple Myeloma (Abstract #8517)

This study of CyBorD was designed to determine response in patients with newly diagnosed multiple myeloma. The results showed the status of 28 evaluable patients, who received cyclophosphamide at 300 mg/m2 on days 1, 8, 15, 22, VELCADE at 1
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
(Date:7/13/2014)... 2014 According to the Living With ... a comprehensive guide that features a series of tips ... (keratosis pilaris). This guide consists of 14 chapters ... Pilaris? ,     Chapter 2: What Cause KP? , ... Have KP? ,     Chapter 4: Keratosis Pilaris Treatment ...
(Date:7/12/2014)... NY (PRWEB) July 12, 2014 The ... growth over the past five years, buoyed by stable ... sector's supply management system. “Eggs are a relatively affordable ... per capita egg consumption generally grows in line with ... Analyst Will McKitterick. Furthermore, demand for new specialty egg ...
(Date:7/12/2014)... By Dennis Thompson ... -- There,s no way to guarantee that a surgical technique ... tiny incisions won,t increase the risk of spreading cancer to ... Friday. The advisory panel to the Food and Drug ... -- called laparoscopic power morcellation -- should sign a written ...
(Date:7/12/2014)... 12, 2014 The fastest-growing mobile technology ... and measurement of LTE networks continues to grow due ... smart devices have increased mobile data traffic, which is ... (CT&M) market. Communications Test and Measurement equipment comply with ... The Communications Test and Measurement Market is estimated to ...
Breaking Medicine News(10 mins):Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5
... PHILADELPHIA Black cardiac arrest victims are more likely to ... large black population than when they,re brought to hospitals with ... from the University of Pennsylvania School of Medicine. The study ... Heart Journal . The Penn team found that, among ...
... INDIANAPOLIS William M. Tierney, M.D., president and CEO ... effectiveness research at the Indiana University School of Medicine, ... Clinical and Translational Research and Education Meeting on April ... National Award for Career Achievement and Contribution to Clinical ...
... Rockville, MD The Association for Research in Vision and ... recipients. These award recipients will be acknowledged at the ARVO ... Fla. Proctor Medal: Robert E. Anderson, MD, PhD, ... de Jong, MD, PhD, FEBOpht, FARVO, Friedenwald Award: James T. ...
... News) -- Women in powerful positions are just as likely as ... It,s widely believed that men are more likely than women to ... important factor than gender, according to the study published April 28 ... a lot of research in the past that indicates that gender ...
... scan with IV contrast and rectal balloon is highly ... values in prostate cancer patients with a rising or ... presented April 29, 2011, at the Cancer Imaging and ... by the American Society for Radiation Oncology (ASTRO) and ...
... combining a patient,s CT scans and 3D printing technology ... printing technology is a fast and affordable way to ... to transform ultra high-resolution CT patient images into 3D ... in architecture, engineering and construction. An advantage of 3-D ...
Cached Medicine News:Health News:Black cardiac arrest patients more likely to be admitted to hospitals with lowest survival rates 2Health News:Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2Health News:2011 ARVO Award recipients honored at annual meeting 2Health News:2011 ARVO Award recipients honored at annual meeting 3Health News:Powerful Women as Likely to Cheat as Men, Study Finds 2Health News:MRI locates prostate cancer recurrence at extremely low PSA levels 2
... SET LNOP Blue Sensor is the first ... The LNOP Blue sensor is the first ... for cyanotic infants and children. Cyanotic ... conditions for reliable and accurate pulse oximetry, ...
Inquire...
... The Trinity Biotech Captia™ Varicella- Zoster ... (ELISA) is intended for the detection and ... in human sera. Individual serum specimens may ... status. Paired sera, acute and convalescent, may ...
ELISA kit for Varicella-zoster IgG....
Medicine Products: